New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 16, 2013
13:55 EDTA, A, STJ, STJ, NUVA, NUVA, JNJ, JNJ, EW, EW, COV, COV, BCR, BCR, BAX, BAX, AFFX, AFFX, SYK, SYKBofA/Merrill's healthcare analysts to hold an analyst/industry conference call
Medical Technology Analyst Hopkins, Life Science Tools Analyst de Bruin and Ketner preview 4Q12 earnings season and discuss upcoming catalysts such as Covidien's spin-off of Mallinckrodt, on an Analyst/Industry conference call to be held on January 16 at 2 pm.
News For A;AFFX;BAX;BCR;COV;EW;JNJ;NUVA;STJ;SYK From The Last 14 Days
Check below for free stories on A;AFFX;BAX;BCR;COV;EW;JNJ;NUVA;STJ;SYK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 14, 2014
16:08 EDTAAgilent sees Q4 EPS 87c-91c, consensus 94c
Subscribe for More Information
16:06 EDTAAgilent reports Q3 EPS 78c, consensus 74c
Subscribe for More Information
15:03 EDTANotable companies reporting after market close
Subscribe for More Information
08:07 EDTBAXKamada sees FY14 revenue $70M-$72M, consensus $75.4M
Kamada (KMDA) expects FY14 revenue $70M-$72M, with revenue from its Distribution Segment projected to be between $25M-$26M and revenue from its Proprietary Products Segment to be between $45M-$47M. The company notes that U.S. revenues from the agreement with Baxter (BAX) remain on track.
07:27 EDTCOVJPMorgan a buyer of Medtronic at current levels
Subscribe for More Information
06:15 EDTCOVCovidien risk/reward very favorable, says Citigroup
Subscribe for More Information
August 12, 2014
10:00 EDTSYKOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:35 EDTJNJActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL GOOG C TSL EXAS BAC DNDN JNJ TSLA
06:22 EDTSYKStryker upgraded to Buy from Hold at Needham
Subscribe for More Information
August 8, 2014
17:10 EDTCOVMarket finishes week up slightly as earnings offset by political events
Stocks finished the week fractionally higher than where they started as strong corporate earnings reports and better than expected economic data was weighed against concerns about geopolitical issues and negative M&A news. MACRO NEWS: A few ongoing geopolitical conflicts worried investors and weighed on shares. Russia unveiled sanctions against Western countries, banning the import of a wide range of food items from the U.S, the EU and a few allied countries in response to sanctions recently enacted against it from G7 nations... President Obama authorized the bombing of rebels in Iraq and Hamas and Israel failed to reach a permanent truce... An ISM services index, the U.S. trade deficit for June, and weekly jobless claims were all better than expected. Meanwhile, the increase in unit labor costs last quarter came in below the consensus outlook, perhaps easing fears that the Fed will need to raise interest rates sooner than expected. COMPANY NEWS: On the M&A front, two huge potential deals fell through as 21st Century Fox (FOX, FOXA) withdrew its offer to acquire Time Warner (TWX) and Sprint (S) reportedly decided to end its pursuit of a merger with peer T-Mobile (TMUS)... President Obama indicated that his administration would take unilateral steps in an effort to prevent companies from carrying out tax inversion acquisitions. Among the deals or possible transactions that involve inversion are Medtronic's (MDT) acquisition of Covidien (COV), Valeant's (VRX) proposed takeover of Allergan (AGN) and Mylan's (MYL) acquisition of Abbott's (ABT) developed markets branded generics pharmaceuticals business. Meanwhile, Walgreen's (WAG) stock tumbled after the U.S. company said it would not structure its takeover of European drugstore chain Alliance Boots as a tax inversion deal... 21st Century Fox, 3D printer maker Stratasys (SSYS), chip maker NVIDIA (NVDA), brewer Molson Coors (TAP), and luxury accessories maker Coach (COH) all rose following their earnings reports. Conversely, Target (TGT), luxury accessories maker Michael Kors (KORS) and Internet coupon provider Groupon (GRPN) fell following their results or guidance... Gannett (GCI) struck a deal to acquire the remaining 73% interest in Classified Ventures, whose primary asset is the online car shopping website Cars.com, for $1.8B from the other partners in the venture, which include McClatchy (MNI), Tribune Media (TRBAA), Graham Holdings (GHC) and A. H. Belo (AHC). Gannett also announced plans to spin-off its Publishing business, which includes USA Today, through a tax-free distribution to shareholders... McDonald's (MCD) stock was little changed after the company reported that its comparable store sales fell 2.5% in July, which was significantly worse than expected. Food quality issues weighed on the fast food company's sales in Asia and as a result of the China supplier issue, the company warned its previously issued global comparable sales forecast for 2014 is now at risk. INDEXES: The Dow finished the week up 0.35% to 16,553.93, the S&P 500 rose 0.32% to 1,931.59, and the Nasdaq gained 0.41% to 4,370.90.
10:36 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
09:01 EDTJNJJohnson & Johnson remains undervalued, says Cowen
Subscribe for More Information
07:01 EDTCOVHarvard professor says Treasury can reduce inversion incentives, NY Times says
Subscribe for More Information
August 7, 2014
16:30 EDTSTJVolcano settles with St. Jude, to seek divestiture of Axsun
Volcano (VOLC) announced that it will be seeking a divestiture of its Axsun Technologies subsidiary. In addition, the company said that it and St. Jude Medical (STJ) have agreed to settle all existing litigation between the two companies. Under terms of the settlement with St. Jude Medical, the parties have agreed to dismiss their lawsuits with prejudice, with neither party admitting liability to the other. Each party will be granted a release of liability for alleged misconduct, granted a license to all patents-in-suite and granted a covenant not to sue as to various current and future products. As part of the settlement agreement, no financial payments will be made to either party by the other.
13:24 EDTSYKStryker upcoming analyst day may be catalyst for shares, says Argus
Argus believes Stryker is well positioned to post stronger sales and earnings in the second half of the year as new products launch and surgical volume rebounds. The firm thinks the company's analyst day on September 17 could be a catalyst for the shares and it maintains its Buy rating and $102 price target on the stock.
10:51 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
09:03 EDTBAXBaxter opens biologics facility in Singapore
Baxter International announced the formal opening of its first advanced recombinant biologic facility in Singapore, and expansion plans for a new recombinant protein processing suite. The current suite supports the processing of ADVATE.The second suite will initially process RIXUBIS, a recombinant factor IX protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval. The Singapore facility received regulatory approval from the European Medicines Agency in January 2014 for the production of ADVATE2. This allows the facility to process and supply ADVATE to the European Union, Iceland and Norway. The biologics facility in Singapore currently employs more than 400 production staff and expects to reach 450 by 2015 to support the second processing suite.
08:58 EDTCOVMedtronic receives request of additional info from FTC for Covidien acquisition
On August 6, 2014, in connection with the FTC review of the pending acquisition by Medtronic (MDT) of Covidien (COV), which will result in both Medtronic and Covidien becoming wholly owned subsidiaries of Medtronic, Medtronic received a request for additional information and documentary material from the FTC. Issuance of the second request extends the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 until 30 days after Medtronic and Covidien have substantially complied with the second request, unless the waiting period is extended voluntarily by the parties or terminated earlier by the FTC. Medtronic and Covidien intend to cooperate fully with the FTC and continue to expect the Transaction to be completed in the fourth calendar quarter of 2014 or early 2015.
08:16 EDTSTJSt. Jude Medical completes acquisition of NeuroTherm
Subscribe for More Information
06:42 EDTCOVObama to look to limit inversion deals, Politico says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use